NYSEAMERICAN:ARMP Armata Pharmaceuticals Q1 2026 Earnings Report $4.18 +0.08 (+1.95%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$4.17 -0.01 (-0.26%) As of 09/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Armata Pharmaceuticals EPS ResultsActual EPS-$3.16Consensus EPS -$0.38Beat/MissMissed by -$2.78One Year Ago EPSN/AArmata Pharmaceuticals Revenue ResultsActual Revenue$0.79 millionExpected Revenue$0.74 millionBeat/MissBeat by +$49.00 thousandYoY Revenue GrowthN/AArmata Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time8:00AM ETUpcoming EarningsArmata Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Armata Pharmaceuticals Earnings HeadlinesArmata Wins FDA Breakthrough Therapy Designation For AP-SA02 In Complicated SAB; Stock UpSeptember 14, 2026 | rttnews.comArmata Pharmaceuticals' AP-SA02 Gets FDA Breakthrough Therapy DesignationSeptember 14, 2026 | marketscreener.comMThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.September 19 at 1:00 AM | Porter & Company (Ad)Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial TreatmentSeptember 14, 2026 | marketscreener.comMArmata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02September 14, 2026 | prnewswire.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | prnewswire.comSee More Armata Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email. Email Address About Armata PharmaceuticalsArmata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for serious bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria. Armata’s approach is intended to address drug-resistant infections while limiting disruption to beneficial bacteria. The company’s pipeline has included inhaled phage products designed to treat chronic respiratory infections caused by Pseudomonas aeruginosa, including infections associated with cystic fibrosis and other structural lung diseases. Armata has also developed phage-based candidates targeting Staphylococcus aureus infections, including serious systemic infections. Its work includes phage discovery, selection and engineering, formulation, and the clinical development of pathogen-specific treatments. Armata is based in Marina del Rey, California, and serves the biotechnology and healthcare markets through research and clinical development activities. The company was formerly known as Synthetic Biologics, Inc. and adopted the Armata Pharmaceuticals name as it concentrated its operations on bacteriophage therapeutics. Because its products remain in development, their availability and approved uses depend on the results of clinical trials and regulatory review.View Armata Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
